ENANTA PHARMACEUTICALS INC — Director's Dealing 2022

Feb 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENANTA PHARMACEUTICALS INC (ENTA)
CIK: 0001177648
Period of Report: 2022-02-14

Reporting Person: MELLETT PAUL J (Treasurer and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-14	Common Stock	A	615	—	Acquired	56617	Direct
2022-02-14	Common Stock	A	2419	—	Acquired	59036	Direct
2022-02-14	Common Stock	F	958	$62.49	Disposed	58078	Direct

Footnotes

F1: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022.

F2: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022.

F3: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.